Preventing Sudden Cardiac Death.
Saving Lives.
A breakthrough technology to identify at-risk individuals before it’s too late.
Sudden Cardiac Death: A Major Risk That Remains Unpredictable
Each year, sudden cardiac death (SCD) remains one of the leading causes of adult mortality worldwide. It is estimated to cause more than 300,000 deaths per year in Europe or the United States — more than cancers (lung, breast, …) taken individually.
SCD accounts for 10% of adult mortality in Western countries, often in patients who showed no prior symptoms. Despite advances in cardiology, imaging, and genetics, current risk assessment methods remain insufficient to identify the most vulnerable individuals. The paradox is that highly effective treatments exist to protect at-risk patients, such as implantable cardioverter-defibrillators, ablation techniques, or medications.
Incidence Europe: approx. 300,000 cases/year
Incidence USA: 300 – 400,000 cases/year
In France: approximately 50,000 cases/year
70 to 80% of sudden cardiac death victims were not identified as at-risk based on ECG or echocardiographic examinations
Implantable cardioverter-defibrillators (ICDs) can terminate more than 97% of lethal arrhythmias.
PulsHeart develops a non-invasive medical system to detect individuals at high risk of sudden cardiac death
PulsHeart (spin-off from IHU Liryc and founded in 2022 by Prof. Haïssaguerre) develops non-invasive and affordable solutions to identify patients at risk of sudden cardiac death (SCD).
Our medical device is a new generation of ECG device combined with advanced signal processing & AI methods. Our ambition is to provide healthcare professionals with precise diagnostic and predictive indicators to transform prevention and save lives before it’s too late.
